Inclusion Criteria:

- Informed consent form signed prior to study entry

- Age between 18-69 years old

- Pathology approved to be nasopharyngeal carcinoma (types WHO Ⅱ-Ⅲ)

- Stage Ⅲ, Ⅳa, Ⅳb according to UICC (International Union Against Cancer) 2002 6th
edition criteria

- Primary tumor measurable

- KPS score ≥80

- Expected life span ≥6 months

- Adequate bone marrow function: White Blood
Cell≥4×109/L，Hemoglobin≥100g/L，Platelet≥100×109/L

- Adequate liver function: ALAT/ASAT＜1.5 × upper limit of normal (ULN), bilirubin
＜1.5×ULN

- Adequate renal function: Creatinine Clearance < 1.5×ULN

Exclusion Criteria:

- Evidence of distant metastatic disease

- Surgical procedure of the primary tumor or lymph nodes (except diagnostic biopsy)

- Previous radiotherapy for the primary tumor or lymph nodes

- Previous exposure to epidermal growth factor-targeted therapy

- Prior chemotherapy or immunotherapy for the primary tumor

- Other previous malignancy within 5 years, except non-melanoma skin cancer or
pre-invasive carcinoma of the cervix

- Any investigational agent prior to the 1st study medication

- Participation in another clinical study within the 30 days prior to Inclusion in this
study.

- Peripheral neuropathy > grade 1

- Known grade 3 or 4 allergic reaction to any of the study treatment

- History of severe pulmonary or cardiac disease

- Creatinine Clearance < 30ml/min

- Know drug abuse / alcohol abuse

- Legal incapacity or limited legal capacity

- Active systemic infection

- Medical or psychiatric illness, which in the investigators' opinions, would not
permit the subject to complete or fully and completely understand the risks and
potential complications of the study

- Concurrent chronic systemic immune therapy or hormone therapy not indicated in the
study protocol

- Pregnancy (confirmed by serum or urine β-HCG) or lactation period

- Severe intercurrent illness, e.g. uncontrolled hypertension, cardiac failure